## Andrew C Don-Wauchope

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8194120/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Cross-Platform Metabolomics Comparison Identifies Serum Metabolite Signatures of Liver Fibrosis Progression in Chronic Hepatitis C Patients. Frontiers in Molecular Biosciences, 2021, 8, 676349.	3.5	11
2	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	1.7	324
3	Commentary on A Rare Cause of Virilization, Short Stature, and Hypertension. Clinical Chemistry, 2020, 66, 1493-1494.	3.2	0
4	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	1.7	474
5	Assessment of the Measurement Error in Cyclosporine Levels Drawn Between Peripheral and Central Sources. American Journal of Clinical Pathology, 2018, 149, 76-81.	0.7	3
6	Rates of inappropriate laboratory test utilization in Ontario. Clinical Biochemistry, 2017, 50, 822-827.	1.9	39
7	Evaluation of a chemiluminescent immunoassay for urinary aldosterone on the DiaSorin LIAISON automated platform against RIA and LC-MS/MS. Clinical Chemistry and Laboratory Medicine, 2017, 55, e181-e183.	2.3	4
8	Clinical implications of estrone sulfate measurement in laboratory medicine. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 73-86.	6.1	11
9	Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM) – does it leverage any advantage in clinical decision making?. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 471-494.	6.1	110
10	Commutable samples with assigned target concentrations may help us harmonise general chemistry results. Clinical Chemistry and Laboratory Medicine, 2017, 55, 165-166.	2.3	2
11	Frameshift mutation in the APOA5 gene causing hypertriglyceridemia in a Pakistani family: Management and considerations for cardiovascular risk. Journal of Clinical Lipidology, 2016, 10, 1272-1277.	1.5	6
12	Familial partial lipodystrophy presenting as metabolic syndrome. Journal of Clinical Lipidology, 2016, 10, 1488-1491.	1.5	22
13	Lot change for reagents and calibrators. Clinical Biochemistry, 2016, 49, 1211-1212.	1.9	12
14	Acceptable Analytical Variation May Exceed High-Sensitivity Cardiac Troponin I Cutoffs in Early Rule-Out and Rule-In Acute Myocardial Infarction Algorithms. Clinical Chemistry, 2016, 62, 887-889.	3.2	47
15	Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 364-389.	3.6	1,166
16	Error detection in routine clinical chemistry laboratory test results. Clinical Biochemistry, 2016, 49, 199-200.	1.9	2
17	Evaluation of natriuretic peptide recommendations in heart failure clinical practice guidelines. Clinical Biochemistry, 2016, 49, 8-15.	1.9	6
18	Laboratory challenges in primary aldosteronism screening and diagnosis. Clinical Biochemistry, 2015, 48, 377-387.	1.9	68

#	Article	IF	CITATIONS
19	Successful reintroduction of statin therapy after statin-associated rhabdomyolysis. Journal of Clinical Lipidology, 2015, 9, 594-596.	1.5	5
20	Evidence based application of BNP/NT-proBNP testing in heart failure. Clinical Biochemistry, 2015, 48, 236-246.	1.9	39
21	Grading Evidence for Laboratory Test Studies Beyond Diagnostic Accuracy: Application to Prognostic Testing. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2015, 26, 168-82.	0.7	0
22	Within-run precision and outlier detection for the Abbott ARCHITECT cardiac troponin I assay. Annals of Clinical Biochemistry, 2014, 51, 512-514.	1.6	11
23	Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Failure Reviews, 2014, 19, 421-438.	3.9	91
24	BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Failure Reviews, 2014, 19, 453-470.	3.9	164
25	BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Failure Reviews, 2014, 19, 471-505.	3.9	82
26	Incremental predictive value of natriuretic peptides for prognosis in the chronic stable heart failure population: a systematic review. Heart Failure Reviews, 2014, 19, 521-540.	3.9	18
27	Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review. Heart Failure Reviews, 2014, 19, 507-519.	3.9	22
28	Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. Heart Failure Reviews, 2014, 19, 439-451.	3.9	56
29	Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review. Heart Failure Reviews, 2014, 19, 541-551.	3.9	6
30	B-type natriuretic peptide-guided therapy: a systematic review. Heart Failure Reviews, 2014, 19, 553-564.	3.9	37
31	A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. Heart Failure Reviews, 2014, 19, 413-419.	3.9	64
32	Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. European Journal of Clinical Nutrition, 2014, 68, 416-423.	2.9	255
33	Dual Reporting of Hemoglobin A1C in the Canadian Journal of Diabetes. Canadian Journal of Diabetes, 2014, 38, 161-163.	0.8	0
34	Applicability of the AGREE II Instrument in Evaluating the Development Process and Quality of Current National Academy of Clinical Biochemistry Guidelines. Clinical Chemistry, 2012, 58, 1426-1437.	3.2	26
35	Improving serological test ordering patterns for the diagnosis of celiac disease through clinical laboratory audit of practice. Clinical Biochemistry, 2012, 45, 455-459.	1.9	13
36	Position statement of the Canadian Society of Clinical Chemists and Canadian Association of Medical Biochemists on hemoglobin A1c measurement and reporting. Clinical Biochemistry, 2012, 45, 1036-1037.	1.9	5

#	Article	IF	CITATIONS
37	Missed follow-up opportunities using a two-step screening approach for gestational diabetes. Diabetes Research and Clinical Practice, 2012, 96, e43-e46.	2.8	27
38	Reporting of post-polyethylene glycol prolactin: precipitation by polyethylene glycol 6000 or polyethylene glycol 8000 will change reference intervals for monomeric prolactin. Annals of Clinical Biochemistry, 2012, 49, 402-404.	1.6	12
39	Adverse metabolic effects of a hypercaloric, high-fat diet in rodents precede observable changes in body weight. Nutrition Research, 2011, 31, 707-714.	2.9	27
40	Testing for Gluten-Related Disorders in Clinical Practice: The Role of Serology in Managing the Spectrum of Gluten Sensitivity. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 193-197.	1.7	32
41	State hospitals, academic medicine and the decline of health care in South Africa: A cry of support from those who have left for those who stay South African Medical Journal, 2010, 100, 74.	0.6	Ο
42	Review of the prevalence of macroprolactinaemia in a South African hospital. Clinical Chemistry and Laboratory Medicine, 2009, 47, 882-4.	2.3	2
43	Laboratory defined critical value limits: How do hospital physicians perceive laboratory based critical values?. Clinical Biochemistry, 2009, 42, 766-770.	1.9	24
44	The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw. Clinical Biochemistry, 2009, 42, 1194-1196.	1.9	14
45	Bone turnover markers in the management of postmenopausal osteoporosis. Clinical Biochemistry, 2009, 42, 929-942.	1.9	171
46	Pediatric critical values: Laboratory–pediatrician discourse. Clinical Biochemistry, 2009, 42, 1658-1661.	1.9	13
47	Requesting and Interpreting Urine Albumin Measurements in the Primary Health Care Setting. Clinical Chemistry, 2008, 54, 1595-1597.	3.2	4
48	Health in Africa: International experience may provoke animosity towards those returning home. BMJ: British Medical Journal, 2005, 331, 1203.4.	2.3	0
49	Employment contracts for South African doctors. South African Medical Journal, 2005, 95, 542.	0.6	1
50	Clinical and radiological features of patients with macroprolactinaemia. Clinical Endocrinology, 2003, 59, 339-346.	2.4	58
51	Unreliability of triglyceride measurement to predict turbidity induced interference. Journal of Clinical Pathology, 2003, 56, 861-862.	2.0	37
52	Exocytosis Studies in a Chromaffin Cellâ€Free System. Annals of the New York Academy of Sciences, 2002, 971, 257-261.	3.8	8
53	High-efficiency Semliki Forest virus-mediated transduction in bovine adrenal chromaffin cells. Biochemical Journal, 1999, 342, 497-501.	3.7	24
54	High-efficiency Semliki Forest virus-mediated transduction in bovine adrenal chromaffin cells. Biochemical Journal, 1999, 342, 497.	3.7	5